Skip to content

Draft, not yet released. In stewardship review. Not indexed until the first approved release.

Individualised editing outpaces delivery systems

A conditional statement under stated assumptions, never a prediction.

2 min read0 figures0 tables3 notesNR-XTECH-GENOMICS-GLOBAL-2026-BASELINE

فهرست مطالب
  1. ·Edition home
  2. ·Executive summary
  3. 1Genomics is data infrastructure and a therapeutic frontier
  4. 2Key findings
  5. 3Systems and sectors at baseline
  6. 4Risks and capability
  7. 5Individualised editing outpaces delivery systems
    1. 5.1 Assumptions
    2. 5.2 The cascade, step by step
    3. 5.3 The scenario as a table of steps
  8. 6Readings from the other desks
  9. 7The 2027 agenda
  10. 8Systems in depth
  11. Aروش‌شناسی
  12. BData appendix
  13. CReferences and record
  14. ·Complete edition, for print

5.1مفروضات

Scenario SCN-XT05-DLV-01: what is assumed, and what is held constant.

خط پایه
the 2026 reference state in this edition
محرک‌ها
bespoke editing pathways open faster than payment, manufacturing and oversight capacity grow
Analogues
the 2025 patient-specific therapy and the 2025 trial holds459
Interventions
none modelled: the specification describes the unmitigated case
Run state
narrative specification; quantified run scheduled for 2027

5.2The cascade, step by step

  1. 1

    GOV → HLT

    a plausible mechanism pathway lowers the evidence needed for bespoke therapies

    2025

  2. 2

    HLT → FIN

    payers face one-time prices with thin outcome data

    2026

  3. 3

    INF → HLT

    manufacturing and clinic capacity limit who is treated

    2026

  4. 4

    HLT → GOV

    a safety event in a bespoke or in vivo therapy triggers holds

    2025

  5. 5

    TRD → INF

    trade rules change instrument and reagent supply

    2025

  6. 6

    DAT → FIN

    genetic data and biobanks become assets in disputes over ownership

    2025

5.3The scenario as a table of steps

How the shock in scenario SCN-XT05-DLV-01 would travel through Genomics and Gene Editing’s coupled systems, step by step, under the assumptions the edition states.

گامآنچه رخ می‌دهدمنبع
01 Governance to healthA plausible mechanism pathway lowers the evidence needed for bespoke therapies. Analogue or source: 2025.Edition XT-05, scenario SCN-XT05-DLV-01, step 1
02 Health to financePayers face one-time prices with thin outcome data. Analogue or source: 2026.Edition XT-05, scenario SCN-XT05-DLV-01, step 2
03 Infrastructure to healthManufacturing and clinic capacity limit who is treated. Analogue or source: 2026.Edition XT-05, scenario SCN-XT05-DLV-01, step 3
04 Health to governanceA safety event in a bespoke or in vivo therapy triggers holds. Analogue or source: 2025.Edition XT-05, scenario SCN-XT05-DLV-01, step 4
05 Trade to infrastructureTrade rules change instrument and reagent supply. Analogue or source: 2025.Edition XT-05, scenario SCN-XT05-DLV-01, step 5
06 DAT to financeGenetic data and biobanks become assets in disputes over ownership. Analogue or source: 2025.Edition XT-05, scenario SCN-XT05-DLV-01, step 6

A teaching model of a conditional scenario under the edition’s stated assumptions: not a forecast, not a prediction and not a warning. Sources: Genomics and Gene Editing 2026, scenario SCN-XT05-DLV-01 (2026); Genomics and Gene Editing 2026, references (NR-CIT-1) (2026).

Notes

Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references

  1. 4Musunuru, K. et al., Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease, New England Journal of Medicine 2025 (abstract read through the Europe PMC record; one infant, two infusions at about 7 and 8 months of age). Massachusetts Medical Society, Waltham. Observation year 2025. Accessed 2026-11-03.back
  2. 5Clinical Trials Arena (ed.), FDA unveils new pathway to usher bespoke therapies to market (trade press, 13 November 2025; describes the plausible mechanism pathway announced in a journal article by the FDA Commissioner and the CBER Director; secondary report, weak evidence). Clinical Trials Arena, London. Observation year 2025. Accessed 2026-11-03.back
  3. 9BioSpace (ed.), Life-threatening liver toxicity triggers FDA freeze on two Intellia gene therapy studies (trade press, 30 October 2025; relays company disclosures; secondary report, weak evidence). BioSpace, Boston. Observation year 2025. Accessed 2026-11-03.back

Downloads

Draft, not yet releasedReview copies of a draft in stewardship review. The released edition carries its DOI and replaces them.

  • چاپ

    • PDF, A4

      The designed print edition, A4: cover, imprint and licence, how to cite, contents with page numbers, every chapter, figure, table and annex.

      PDF113 pages1.0 MBTagged, with bookmarks

      SHA-256 7276b0b0c2919661f94a296cdb60a579d1cb5466d3fab3011f46a9d5e81e42d6

    • PDF, US Letter

      The designed print edition, US Letter: cover, imprint and licence, how to cite, contents with page numbers, every chapter, figure, table and annex.

      PDF123 pages1.0 MBTagged, with bookmarks

      SHA-256 da38a3579fdd5a3ac5c84f44a22853584be7e987208657578ede146f7b88fd58

  • Web edition

  • Data bundle

    • Indicators, CSV

      16 indicators with unit, year, status and source

      NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE-indicators.csv1 KB

      SHA-256 f1c3fc5ae9f6823c263bb4a464c29a9516551ab806ef2a07fc3e737d1cd85a8d

    • Indicators, JSON

      The same indicators with the edition’s identity and licence

      NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE-indicators.json2 KB

      SHA-256 c54a918f9a805a488a8931ec6c1a235eb273361704df0909aae23d83048aa489

    • Findings, CSV

      12 findings with status, evidence-quality level and references

      NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE-findings.csv3 KB

      SHA-256 0cb51833261dd188ca2af8a452aa38bbf651743f01a98776ff39430d07bcb97f

  • Citation files

    • Citation, BibTeX

      For LaTeX and reference managers

      NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE.bib1 KB

      SHA-256 a09328c6428b83ba58eba3284cc50b50417b9fccd1c4d685a53746ed430fac83

    • Citation, RIS

      For Zotero, EndNote and Mendeley

      NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE.ris1 KB

      SHA-256 95ff0d92b09d48fa348d982302647ab3ab0709cf5aaccccde30e735cade45a16

    • Citation, CITATION.cff

      Citation File Format 1.2.0, for GitHub, Zenodo and software catalogues

      NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE.cff1 KB

      SHA-256 16aeb56c4b5eb0bfe8917c7848aec9209776f6cf7708280877069c0cfe0ef1f2

Check a file with its SHA-256: shasum -a 256 <file> (macOS, Linux) or Get-FileHash <file> (Windows). Text, tables and figures by Nexus: CC BY 4.0; each source keeps its own licence.

Cite this chapter

Valadbaygi, S. (Ed.). (2026). Chapter 5: Individualised editing outpaces delivery systems. In Exponential Technology Report 2026: Genomics and Gene Editing (Baseline Edition 2026, Report No. NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE) [Draft under review]. The Global Centre for Risk and Innovation (GCRI).

Every citation form of the whole report, BibTeX and RIS included, is on the edition home. Cite this report

گزارش‌هامشارکت

Send evidence or a correction on Genomics and Gene Editing.

Reports is the Consortium’s quarterly publication, written by six desks. This page sits with the Global Centre for Risk and Innovation (GCRI) Systems Evidence desk. What you know about this subject can become evidence, a case or a correction in the next edition, credited to you and published under CC BY 4.0 where it is your own work. Sent to the wrong desk, it is forwarded, not refused.

میز شواهد سامانه‌های GCRIفناوری نمایی

CC BY 4.0 Free to read. Text and figures: CC BY 4.0. Data: CC0 1.0. Authors keep copyright. Published by GCRI Canada.

Your role here

What you can do from this page.

  • ReaderFound an error? Every correction is public.Corrections log
  • ContributorSend evidence, data or a correction to this desk.Contribute
  • ReviewerReview for this desk; verified reviews are credited.Become a reviewer
  • Editor, steward or boardQueues, decisions and production are in the workspace.My workspace